- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07724938
Combination Tonsillectomy and Hypoglossal Nerve Stimulation for OSA Patients With Lateral Pharyngeal Collapse (HGNS+T)
The goal of this clinical trial is to learn whether removing the tonsils at the time of hypoglossal nerve stimulation improves treatment of obstructive sleep apnea in adults whose airway collapses from the side of the upper airway during sleep. The main questions it aims to answer are:
- Does hypoglossal nerve stimulation combined with tonsillectomy reduce the severity of obstructive sleep apnea more than hypoglossal nerve stimulation alone?
- Does tonsillectomy improve how effectively hypoglossal nerve stimulation opens and stabilizes the upper airway?
Researchers will compare participants who receive hypoglossal nerve stimulation with tonsillectomy to participants who receive hypoglossal nerve stimulation alone.
Participants will:
- Complete sleep studies, questionnaires, and other assessments before and after treatment
- Be randomly assigned to receive hypoglossal nerve stimulation either with or without tonsillectomy
- Return for follow-up visits and sleep testing to evaluate treatment effectiveness
- In a subset of participants, complete additional overnight testing to measure how treatment changes upper-airway collapsibility
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Obstructive sleep apnea (OSA) is commonly treated with hypoglossal nerve stimulation (HGNS), but treatment efficacy is substantially reduced in patients with complete oropharyngeal lateral wall (OPLW) collapse. HGNS primarily enlarges the airway by protruding the tongue and is therefore most effective in patients with anteroposterior patterns of airway collapse. Tonsillectomy reduces tissue contributing to lateral pharyngeal narrowing and may complement the mechanism of HGNS by addressing residual lateral wall obstruction. Preliminary clinical data suggest that combining tonsillectomy with HGNS substantially improves treatment response compared with HGNS alone in patients with OPLW collapse, but this strategy has not been evaluated in a randomized clinical trial.
This prospective, randomized controlled trial will enroll 72 adults with moderate-to-severe OSA, complete OPLW collapse identified on drug-induced sleep endoscopy, and candidacy for both HGNS implantation and tonsillectomy. Participants will be randomized 1:1 to receive either concurrent HGNS implantation plus tonsillectomy or HGNS implantation alone. All participants will undergo standard postoperative device activation and titration. The primary efficacy endpoint will be assessed after approximately one month of optimized HGNS therapy using sleep studies and patient-reported outcomes. Participants in the HGNS-alone group with persistent OSA may subsequently undergo delayed tonsillectomy as part of standard clinical care, permitting additional within-subject mechanistic comparisons.
The primary objective is to determine whether concurrent tonsillectomy improves the effectiveness of HGNS in reducing OSA severity compared with HGNS alone. Secondary objectives are to determine whether tonsillectomy enhances HGNS-induced improvements in upper-airway collapsibility and to evaluate whether tonsillectomy modifies the physiological effects of HGNS beyond the effects of either treatment alone. In an optional mechanistic substudy, approximately 30 participants will undergo detailed physiological sleep studies to measure pharyngeal collapsibility using gold-standard techniques, providing insight into the mechanisms underlying any observed improvement in clinical outcomes.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Dillon Gilbertson, BASc
- Número de telefone: 617-732-6488
- E-mail: dgilbertson@bwh.harvard.edu
Estude backup de contato
- Nome: Daniel Vena, PhD
- Número de telefone: 16178520719
- E-mail: dvena@bwh.harvard.edu
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Recrutamento
- Brigham and Women's Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of obstructive sleep apnea with apnea-hypopnea index (AHI) ≥ 15 events/hour
- Complete oropharyngeal lateral wall (OPLW) collapse identified on DISE
- Candidate for HGNS implantation based on standard clinical criteria
- Presence of small (1-2+) tonsils and eligibility for tonsillectomy
- Untreated OSA at the time of enrollment
- Willing and able to provide written informed consent
Exclusion Criteria:
- Absence of tonsils
- Presence of large tonsils (3-4+; not eligible for HGNS)
- Predominant central or mixed sleep apnea (>25% central or mixed events)
- Any unstable or serious medical condition that, in the opinion of the investigator, would increase risk or interfere with study participation
- Ineligibility for HGNS implantation based on standard clinical or surgical criteria
- Inability to comply with study procedures or follow-up assessments
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: HGNS plus tonsillectomy
HGNS plus concomitant tonsillectomy
|
Amigdalectomia
HGNS alone (without concomitant tonsillectomy)
|
|
Comparador Ativo: HGNS
HGNS alone (without concomitant tonsillectomy)
|
HGNS alone (without concomitant tonsillectomy)
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percent reduction in apnea-hypopnea index (AHI)
Prazo: 1 month of optimized therapy.
|
Percent reduction in the apnea-hypopnea index (AHI), measured by overnight polysomnography, from baseline to the primary follow-up sleep study.
Higher values indicate greater improvement in obstructive sleep apnea.
|
1 month of optimized therapy.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Absolute change in apnea-hypopnea index
Prazo: 1 month of optimized therapy.
|
Absolute change in the apnea-hypopnea index (AHI), measured in events per hour by overnight polysomnography, from baseline to the primary follow-up sleep study.
Negative values indicate improvement in obstructive sleep apnea.
|
1 month of optimized therapy.
|
|
Treatment success
Prazo: 1 month of optimized therapy
|
Treatment success is defined as a ≥50% reduction in the apnea-hypopnea index (AHI) from baseline and a follow-up AHI <15 events per hour.
The outcome is reported as the proportion of participants meeting this definition (0-100%), with higher values indicating greater treatment success.
|
1 month of optimized therapy
|
|
Change in Sleep Apnea Hypoxic Burden from Baseline
Prazo: 1 month of optimized therapy
|
Sleep apnea hypoxic burden will be calculated from overnight polysomnography using the validated Azarbarzin method (PMID: 30376054) as the cumulative area under the oxygen desaturation curve associated with apneas and hypopneas, normalized to total sleep time and expressed as %min/hour.
Higher values indicate greater hypoxic burden.
|
1 month of optimized therapy
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
PROMIS Sleep Disturbance
Prazo: 1 month of optimized therapy
|
The PROMIS Sleep Disturbance Short Form 8b assesses perceptions of sleep quality, sleep depth, and difficulties with sleep.
Scores are reported as standardized T-scores (mean = 50 and SD = 10), with higher scores indicating greater sleep disturbance (worse outcome).
|
1 month of optimized therapy
|
|
PROMIS Sleep-Related Impairment
Prazo: 1 month of optimized therapy
|
The PROMIS Sleep-Related Impairment Short Form 8a assesses daytime impairment associated with poor sleep, including sleepiness, fatigue, and reduced alertness.
Scores are reported as standardized T-scores (mean = 50 and SD = 10), with higher scores indicating greater sleep-related impairment (worse outcome).
|
1 month of optimized therapy
|
|
PROMIS Fatigue
Prazo: 1 month of optimized therapy
|
The PROMIS Fatigue Short Form 7a assesses the experience and impact of fatigue on daily functioning.
Scores are reported as standardized T-scores (mean = 50 and SD = 10), with higher scores indicating greater fatigue (worse outcome).
|
1 month of optimized therapy
|
|
Sleep apnea quality of life
Prazo: 1 month of optimized therapy
|
The Sleep Apnea Quality of Life Index (SAQLI) assesses disease-specific quality of life in obstructive sleep apnea.
Total scores range from 1 to 7, with higher scores indicating better sleep-related quality of life (better outcome).
|
1 month of optimized therapy
|
|
Epworth sleepiness scale
Prazo: 1 month of optimized therapy
|
The Epworth Sleepiness Scale assesses subjective daytime sleepiness.
Total scores range from 0 to 24, with higher scores indicating greater daytime sleepiness (worse outcome).
|
1 month of optimized therapy
|
|
VAS treatment satisfaction
Prazo: 1 month of optimized therapy
|
Participants rate overall satisfaction with treatment on a 0-10 visual analog scale, where 0 indicates not at all satisfied and 10 indicates completely satisfied.
Higher scores indicate greater treatment satisfaction (better outcome).
|
1 month of optimized therapy
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Publicações Gerais
- Huyett P, Kent DT, D'Agostino MA, Green KK, Soose RJ, Kaffenberger TM, Woodson BT, Huntley C, Boon MS, Heiser C, Birk A, Suurna MV, Lin HS, Waxman JA, Kezirian EJ. Drug-Induced Sleep Endoscopy and Hypoglossal Nerve Stimulation Outcomes: A Multicenter Cohort Study. Laryngoscope. 2021 Jul;131(7):1676-1682. doi: 10.1002/lary.29396. Epub 2021 Jan 14.
- Vena D, Op de Beeck S, Yang H, Sumner J, Mann D, Wang TY, Aishah A, Azarbarzin A, Messineo L, Calianese N, Alex R, Esmaeili N, Vanderveken OM, White DP, Wellman A, Huyett P, Sands SA. Lateral wall collapse from sleep endoscopy and airflow shape predicts hypoglossal nerve stimulation efficacy in obstructive sleep apnoea. Eur Respir J. 2025 Oct 7;66(4):2500236. doi: 10.1183/13993003.00236-2025. Print 2025 Oct.
- Huyett P, Wellman A, Caruso V, Sumner J, Aishah A, Azarbarzin A, Sands S, Vena D. Combination Tonsillectomy and Hypoglossal Nerve Stimulation for Sleep Apnea Patients With Oropharyngeal Lateral Wall Collapse. Otolaryngol Head Neck Surg. 2024 Dec;171(6):1904-1910. doi: 10.1002/ohn.950. Epub 2024 Aug 27.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Doenças Respiratórias
- Distúrbios Respiratórios
- Distúrbios do Sono Vigília
- Apnéia
- Distúrbios do Sono Intrínsecos
- Dissônias
- Síndromes da Apneia do Sono
- Apnéia do Sono, Obstrutiva
- Procedimentos cirúrgicos, operatórios
- Procedimentos cirúrgicos otorinolaryngológicos
- Amigdalectomia
Outros números de identificação do estudo
- 2026P000343
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .